US expands scope of BI’s lung cancer drug Gilotrif
admin 16th January 2018 Uncategorised 0US regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor.
More: US expands scope of BI’s lung cancer drug Gilotrif
Source: News